Table of Contents

• Free Topics
  • About
  • Acknowledgments
  • Azoles
  • Fluconazole
  • Important Facts
  • Introduction
  • New to the Fifth Edition
• PART I. Considerations with Antibiotic Therapy
  • C1. The Wonderful World of Microbiology
  • C2. General Approach to Infectious Diseases
  • C3. Antibiotic Pharmacokinetics
  • C4. Antibiotic Pharmacodynamics
  • C5. Adverse Consequences of Antibiotic Use
  • C6. Antibiotic Resistance
• PART II. Antibacterial Drugs
  • C7. Beta-Lactams
    • Aminopenicillins
    • Anti-MRSA Cephalosporins
    • Antistaphylococcal Penicillins
    • C10. Fluoroquinolones
    • C11. Aminoglycosides
    • C12. Tetracyclines and Modified Tetracyclines
    • C13. Macrolides
    • C14. Oxazolidinones
    • C15. Nitroimidazoles
    • C16. Nitrofurans and Fosfomycin
    • C17. Streptogramins
    • C18. Cyclic Lipopeptides
    • C19. Folate Antagonists
    • C20. Lincosamides
    • C21. Polymyxins
    • C22. Clostridioides difficile-Specific Agents
    • C7. Beta-Lactams
    • C8. Glycopeptides and Short-Acting Lipoglycopeptides
    • C9. Long-Acting Glycopeptides
    • Carbapenem/Beta-lactamase Inhibitor Combinations
    • Carbapenems
    • Cephalosporin/Beta-lactamase Inhibitor Combinations
    • Cephalosporins
    • First-generation Cephalosporins
    • Fourth-generation Cephalosporins
    • Monobactams
    • Natural Penicillins
    • Penicillin/Beta-lactamase Inhibitor Combinations
    • Penicillins
    • Second-generation Cephalosporins
    • Siderophore Cephalosporin
    • Third-generation Cephalosporins
• PART III. Antimycobacterial Drugs
  • C23. Antimycobacterial Drugs
  • C24. Rifamycins
  • C25. Isoniazid
  • C26. Pyrazinamide
  • C27. Ethambutol
• PART IV. Antifungal Drugs
  • C28. Antifungal Drugs
  • C29. Polyenes
  • C30. Antifungal Antimetabolite
  • C31. Azoles
    • C31. Azoles
    • C32. Echinocandins
    • C33. Terpenoids
    • Fluconazole
    • Isavuconazole
    • Itraconazole
    • Posaconazole
• PART V. Antiviral Drugs
  • C34. Antiviral Drugs
  • C35. Anti-Herpes Simplex Virus and Varicella-Zoster Virus Agents
  • C36. Anti-Cytomegalovirus Agents
  • C37. Anti-Influenza Antivirals
  • C38. Anti-Coronavirus Antivirals
  • C39. Antiretroviral Drugs
    • C39. Antiretroviral Drugs
    • C40. Antiviral Interferons
    • C41. Direct-Acting Anti-Hepatitis C Agents
    • C42. Ribavirin
    • C43. Hepatitis B Nucleoside Analogs
    • C44. Anti-SARS-CoV-2 Antibody Therapies
    • Non-nucleoside Reverse Transcriptase Inhibitors
    • Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
    • Protease Inhibitors
• PART VI. Antiparasitic Drugs
  • C45. Antiparasitic Drugs
  • C46. Quinolines
  • C47. Atovaquone
  • C48. Benzimidazoles
  • C49. Pentamidine
  • C50. Ivermectin
  • C51. Artemisinins
• Appendix
  • APPENDIX 1: Selected Normal Human Flora
  • APPENDIX 2: Spectrum of Activity
  • APPENDIX 3: Empiric Regimens for Common Infections
• Front Matter
  • Acknowledgments
  • Important Facts
  • Introduction
  • New to the Fifth Edition